Literature DB >> 7885376

Cytogenetic response to asbestos fibers in cultured human primary mesothelial cells from 10 different donors.

K Pelin1, A Hirvonen, M Taavitsainen, K Linnainmaa.   

Abstract

The ability of amosite asbestos fibers to induce chromosomal aberrations in human primary mesothelial cells obtained from pleural effusions of 10 noncancerous patients was investigated. The glutathione S-transferase M1 (GSTM1) genotypes of the patients were determined, since the GSTM1 null genotype has been associated with increased susceptibility to lung cancer and chemically induced cytogenetic damage. Four of the patients represented the GSTM1 null genotype, and six the GSTM1 positive genotype. Successful chromosome aberration analyses were obtained from six cases, three of them with the GSTM1 null genotype. The level of aberrant cells in unexposed cultures ranged from 2.0% to 7.5%. Statistically significant increases (2.3-3.0-fold compared to controls) in the number of aberrant cells were observed in two cases only: in one case treated with 1 microgram/cm2 of amosite, and in another treated with 2 micrograms/cm2 of amosite. Cell cultures from four individuals showed minor or no increases in the numbers of aberrant cells in the doses tested (1 and 2 micrograms/cm2). Chromosome breaks were the major type of aberration. The amosite exposed cells with significantly increased aberrations were from patients with GSTM1 positive genotypes. Two cases that showed no cytogenetic response to asbestos fibers were of the GSTM1 null genotype. Thus, our results suggest that the lack of the GSTM1 gene does not render human mesothelial cells more susceptible to chromosomal damage induced by asbestos. GSTM1 null cells appeared, however, to be more sensitive to the growth inhibitory effects of asbestos than did GSTM1 positive cells. Variation in the cytogenetic response of human primary mesothelial cells to asbestos fibers was observed to exist, but the fibers do not appear to be potent inducers of structural chromosomal aberrations in these cells. It remains to be established whether individual sensitivity to asbestos fibers, due to specific genetic traits, exists.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7885376     DOI: 10.1016/0165-1161(95)90015-2

Source DB:  PubMed          Journal:  Mutat Res        ISSN: 0027-5107            Impact factor:   2.433


  7 in total

Review 1.  Role of mutagenicity in asbestos fiber-induced carcinogenicity and other diseases.

Authors:  Sarah X L Huang; Marie-Claude Jaurand; David W Kamp; John Whysner; Tom K Hei
Journal:  J Toxicol Environ Health B Crit Rev       Date:  2011       Impact factor: 6.393

Review 2.  Oncogenes and tumor-suppressor genes in mesothelioma--a synopsis.

Authors:  J F Lechner; J Tesfaigzi; B I Gerwin
Journal:  Environ Health Perspect       Date:  1997-09       Impact factor: 9.031

Review 3.  Biopersistence and potential adverse health impacts of fibrous nanomaterials: what have we learned from asbestos?

Authors:  Vanesa C Sanchez; Jodie R Pietruska; Nathan R Miselis; Robert H Hurt; Agnes B Kane
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2009 Sep-Oct

4.  Toxicity and carcinogenicity mechanisms of fibrous antigorite.

Authors:  Venera Cardile; Laura Lombardo; Elena Belluso; Annamaria Panico; Silvana Capella; Michael Balazy
Journal:  Int J Environ Res Public Health       Date:  2007-03       Impact factor: 3.390

Review 5.  Mechanisms of fiber-induced genotoxicity.

Authors:  M C Jaurand
Journal:  Environ Health Perspect       Date:  1997-09       Impact factor: 9.031

6.  Fluoro-edenite fibers induce expression of Hsp70 and inflammatory response.

Authors:  Venera Cardile; Laura Lombardo; Elena Belluso; Annamaria Panico; Marcella Renis; Antonio Gianfagna; Michael Balazy
Journal:  Int J Environ Res Public Health       Date:  2007-09       Impact factor: 3.390

7.  Mesothelioma: Do asbestos and carbon nanotubes pose the same health risk?

Authors:  Marie-Claude F Jaurand; Annie Renier; Julien Daubriac
Journal:  Part Fibre Toxicol       Date:  2009-06-12       Impact factor: 9.400

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.